0001104659-21-076497.txt : 20210603
0001104659-21-076497.hdr.sgml : 20210603
20210603175616
ACCESSION NUMBER: 0001104659-21-076497
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210601
FILED AS OF DATE: 20210603
DATE AS OF CHANGE: 20210603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bitterman Kevin
CENTRAL INDEX KEY: 0001591747
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 21993901
MAIL ADDRESS:
STREET 1: C/O POLARIS VENTURE PARTNERS
STREET 2: 1000 WINTER STREET, SUITE 3350
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
tm2118278d3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-01
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001591747
Bitterman Kevin
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BLVD, SUITE 350
SOUTH SAN FRANCISCO,
CA
94080
1
0
0
0
Stock Option (Right to Buy)
26.32
2021-06-01
4
A
0
13000
0
A
2031-05-31
Common Stock
13000
13000
D
This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.
/s/ Jonathan Young, attorney-in-fact
2021-06-03